.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX13_GlatiramerAcetate.GlatiramerAcetate .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX13_GlatiramerAcetate.GlatiramerAcetate| name: | GlatiramerAcetate |
| ATC code: | L03AX13 | route: | subcutaneous |
| n-compartments | 1 |
Glatiramer acetate is an immunomodulatory drug used primarily for the treatment of relapsing-remitting multiple sclerosis (RRMS). It is a synthetic mixture of polypeptides composed of four amino acids and works by modifying immune processes thought to be involved in MS. It is still approved and used today for this indication.
No classical pharmacokinetic parameters are available in the literature for glatiramer acetate, as it is rapidly degraded locally after subcutaneous administration and plasma concentrations are undetectable. Data represent known clinical use in adults with multiple sclerosis.
Scott, LJ (2013). Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. CNS drugs 27(11) 971–988. DOI:10.1007/s40263-013-0117-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24129744
Johnston, J, & So, TY (2012). First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview. Drugs 72(9) 1195–1211. DOI:10.2165/11634010-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22642799
Ziemssen, T, et al., & Hohlfeld, R (2001). Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug safety 24(13) 979–990. DOI:10.2165/00002018-200124130-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11735654